HSP90 client proteins, such as receptor tyrosine kinases JAK1/2 (involved in uncontrolled proliferation), AKT (angiogenesis), and IL‐6 (inflammation), play diverse roles in pathogenesis.[43] Therefore, pronounced expression of HSP90 has been detected in almost all classes of cancers as well as benign proliferation like psoriasis.[44] Several HSP90 inhibitors have been developed to in treating cancer and plaque‐type psoriasis but none of them have yet been approved due to different drawbacks. Here, JAK1 is linked to cancer.